ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0693

Comparison of the Cardiovascular Risk in Patients with Vasculitis and Diabetes Mellitus
Abstract Number: 0445

Comparison of the Efficacy, Safety and Immunogenicity of a Proposed Biosimilar MSB11456 with Tocilizumab Reference Product in Moderate-to-severe Rheumatoid Arthritis: Results of a Randomized Double-blind Study
Abstract Number: 1559

Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease
Abstract Number: 1583

Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)
Abstract Number: 1310

Comparison of Two Methotrexate Initiation Strategies in Rheumatoid Arthritis in Current Practice
Abstract Number: 2566

Comparisons of the Risk of Serious Infections Associated with the Different Classes of Targeted Therapies Used in Psoriatic Arthritis Patients: A Nationwide Cohort Study from the French Health Insurance Database
Abstract Number: 2083

Compiled Verbal Feedback as a Novel Mechanism for Faculty Feedback from Rheumatology Fellows-in-Training
Abstract Number: 1605

Complement Activation as a Marker of Thrombosis Risk in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Abstract Number: 0900

Complement Deposition on Extracellular Mitochondria Induces Platelet Activation in Vitro
Abstract Number: 1591

Complement Factor D/Adipsin Knockout Mice Demonstrate Disparate Pain and Structural Damage Phenotypes in Obesity-induced Post Traumatic Osteoarthritis
Abstract Number: 0899

Complement Factor I (CFI) Gene Expression by Kidney Tubular Cells Is Increased in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
Abstract Number: 2494

Complement mRNA Expression in Patients with ANCA-associated Glomerulonephritis
Abstract Number: 1818

Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S
Abstract Number: 1396

Comprehensive Evaluation of the Digital Annular Pulleys: From Ultrasonographical to Anatomical and Histological Evaluation with Special Focus on the Entheses
Abstract Number: 0656

Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].